Pliant Therapeutics Inc (PLRX)
🔔 Watch stock
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
NeutralIn den ausgewerteten SEC-Berichten von Pliant Therapeutics (4 Quartalsberichte 10-Q und 2 Jahresberichte 10-K) findet sich kein wesentlicher KI-Bezug: Das Geschäft ist die klinische Entwicklung integrin-basierter Wirkstoffe (Lead PLN-101095, ein oraler Integrin-Hemmer gegen solide Tumoren); KI ist weder Umsatzquelle noch belegter operativer Baustein noch ein konkret aufs eigene Modell bezogenes Geschäftsrisiko. Die Wirkstoff-Entdeckungsplattform wird als »proprietäre Bibliothek von über 15.000 Integrin-Bindemolekülen« beschrieben, ohne KI oder maschinelles Lernen zu erwähnen. Die einzige Nennung von »artificial intelligence« ist eine generische regulatorische Randbemerkung, dass die US-Arzneimittelbehörde FDA neue Richtlinien zum KI-Einsatz bei der Prüfung von Zulassungsanträgen angekündigt habe — kein Bezug zu Pliants eigenem Geschäftsmodell.
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-K 2026-03-11 · 10-K 2025-03-03 · 10-Q 2026-05-11 · 10-Q 2025-11-06 · 10-Q 2025-08-07 · 10-Q 2025-05-08
Rated on July 9, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.80 | – | 2 | -53.10 | -2,190.80 | -48 | -48 |
| 2025: Q1 | -0.91 | – | 0 | – | – | -49 | -49 |
| 2025: Q2 | -0.70 | – | 0 | – | – | -41 | -41 |
| 2025: Q3 | -0.42 | – | 0 | – | – | -21 | -21 |
| 2025: Q4 | -0.38 | – | 0 | -100.00 | – | -18 | -18 |
| 2026: Q1 | -0.32 | – | 0 | – | – | -19 | -19 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Pliant Therapeutics, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, konzentriert sich auf die Entdeckung und Entwicklung integrinbasierter Therapeutika zur Behandlung solider Tumore.
| Employees | 49 |
|---|---|
| Headquarters | South San Francisco, CA |
| Website | pliantrx.com |
| IPO Date | 3. Jun 2020 |
| Next Earnings | 6. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Bernard Coulie M.B.A., M.D., Ph.D. | President, CEO & Director | 1966 |
| Keith Lamont Cummings M.B.A., M.D. | Chief Financial Officer | 1977 |
| Minnie Kuo | Chief Operating Officer | 1981 |
| Rik Derynck Ph.D. | Scientific Founder & Member of Scientific Advisory Board | – |
| Dean Sheppard M.D. | Scientific Founder & Member of Scientific Advisory Board | – |
| Hal Chapman M.D. | Scientific Founder & Member of Scientific Advisory Board | – |
| Delphine Imbert Ph.D. | Chief Technical Officer | – |
| Christopher S. Keenan | Vice President of Investor Relations & Corporate Communications | – |
| Monica Sandberg Ph.D. | Vice President, Regulatory & Compliance | – |
| Lily Cheung | Chief Human Resources Officer | 1973 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.